<DOC>
	<DOCNO>NCT00338442</DOCNO>
	<brief_summary>This study assess VariZIG™ treatment patient risk develop serious complication chicken pox .</brief_summary>
	<brief_title>Safety Efficacy Varicella Zoster Immune Globulin ( Human ) VariZIG Patients Risk Varicella Infection</brief_title>
	<detailed_description>In individual , chicken pox varicella zoster ( VZV ) infection benign ; however , certain at-risk population immunocompromised patient infant VZV disease produce significant morbidity mortality . In patient , varicella zoster immune globulin ( VZIG ) use prevent reduce severity VZV infection at-risk patient expose individual active infection . Massachusetts Public Health Biologic Laboratories ( Boston , MA ) discontinue manufacture FDA approve VZIG product . Cangene Corporation ( Winnipeg , Canada ) conducting expand access IND protocol VariZIG™ , purify human immune globulin preparation make plasma donor high anti-varicella antibody titer . This study open label , non-randomized , expand access study make VariZIG™ available eligible patient alternative licensed treatment pivotal study conduct . The study begin recruit February 2006 collect safety basic efficacy data 42 day follow VariZIG™ administration . Physicians required ass measure varicella infection well provide study specific documentation .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immune Sera</mesh_term>
	<criteria>Signed informed consent . Cangene Corporation VariZIG™ release requirement . Any following atrisk patient expose varicella within previous 96 hour : Immunocompromised pediatric adult patient . Neonates ( less 1 year age ) preterm infant . Pregnant woman . Newborns whose mother VZV infection shortly delivery ( &lt; 5 day ) ( &lt; 2 day ) delivery . Healthy nonimmune adult Hypersensitivity blood blood product , include intravenous ( IV ) intramuscular ( IM ) human immunoglobulin preparation . Selective immunoglobulin A ( IgA ) deficiency . Evidence VZV infection . Evidence zoster infection . Known immunity VZV ( previous varicella infection varicella vaccination ) Severely thrombocytopenic ( platelet &lt; 50 x 10x9 / L )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Immune compromise</keyword>
	<keyword>Varicella Zoster Virus ( VZV ) Infection</keyword>
	<keyword>Pediatric</keyword>
</DOC>